223 related articles for article (PubMed ID: 11024117)
1. Impaired gamma interferon responses against parvovirus B19 by recently infected children.
Corcoran A; Doyle S; Waldron D; Nicholson A; Mahon BP
J Virol; 2000 Nov; 74(21):9903-10. PubMed ID: 11024117
[TBL] [Abstract][Full Text] [Related]
2. Antibody responses in parvovirus B19 infected patients.
Modrow S; Dorsch S
Pathol Biol (Paris); 2002 Jun; 50(5):326-31. PubMed ID: 12116851
[TBL] [Abstract][Full Text] [Related]
3. Differential IgM response to conformational and linear epitopes of parvovirus B19 VP1 and VP2 structural proteins.
Manaresi E; Zuffi E; Gallinella G; Gentilomi G; Zerbini M; Musiani M
J Med Virol; 2001 May; 64(1):67-73. PubMed ID: 11285571
[TBL] [Abstract][Full Text] [Related]
4. B cell memory is directed toward conformational epitopes of parvovirus B19 capsid proteins and the unique region of VP1.
Corcoran A; Mahon BP; Doyle S
J Infect Dis; 2004 May; 189(10):1873-80. PubMed ID: 15122524
[TBL] [Abstract][Full Text] [Related]
5. Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19.
Söderlund M; Brown CS; Spaan WJ; Hedman L; Hedman K
J Infect Dis; 1995 Dec; 172(6):1431-6. PubMed ID: 7594699
[TBL] [Abstract][Full Text] [Related]
6. Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis.
Azzi A; Manaresi E; Zakrzewska K; DeSantis R; Musiani M; Zerbini M
J Med Virol; 2004 Apr; 72(4):679-82. PubMed ID: 14981773
[TBL] [Abstract][Full Text] [Related]
7. T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity.
Franssila R; Auramo J; Modrow S; Möbs M; Oker-Blom C; Käpylä P; Söderlund-Venermo M; Hedman K
Clin Exp Immunol; 2005 Oct; 142(1):53-61. PubMed ID: 16178856
[TBL] [Abstract][Full Text] [Related]
8. CD4(+) T-cell responses against the VP1-unique region in individuals with recent and persistent parvovirus B19 infection.
Lindner J; Barabas S; Saar K; Altmann D; Pfister A; Fleck M; Deml L; Modrow S
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):356-61. PubMed ID: 16316401
[TBL] [Abstract][Full Text] [Related]
9. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG.
Kerr S; O'Keeffe G; Kilty C; Doyle S
J Med Virol; 1999 Feb; 57(2):179-85. PubMed ID: 9892405
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay.
Bostic JR; Brown KE; Young NS; Koenig S
J Infect Dis; 1999 Mar; 179(3):619-26. PubMed ID: 9952368
[TBL] [Abstract][Full Text] [Related]
11. T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19.
Franssila R; Hedman K
Vaccine; 2004 Sep; 22(27-28):3809-15. PubMed ID: 15315862
[TBL] [Abstract][Full Text] [Related]
12. Anti-VP1 and anti-VP2 antibodies detected by immunofluorescence assays in patients with acute human parvovirus B19 infection.
Pereira RF; Paula WN; Cubel Rde C; Nascimento JP
Mem Inst Oswaldo Cruz; 2001 May; 96(4):507-13. PubMed ID: 11391423
[TBL] [Abstract][Full Text] [Related]
13. A synthetic parvovirus B19 capsid protein can replace viral antigen in antibody-capture enzyme immunoassays.
Kock WC
J Virol Methods; 1995 Sep; 55(1):67-82. PubMed ID: 8576310
[TBL] [Abstract][Full Text] [Related]
14. Detection of parvovirus B19 NS1-specific antibodies by ELISA and western blotting employing recombinant NS1 protein as antigen.
Heegaard ED; Rasksen CJ; Christensen J
J Med Virol; 2002 Jul; 67(3):375-83. PubMed ID: 12116031
[TBL] [Abstract][Full Text] [Related]
15. Antibody response to human parvovirus B19 in patients with primary infection by immunoblot assay with recombinant proteins.
Palmer P; Pallier C; Leruez-Ville M; Deplanche M; Morinet F
Clin Diagn Lab Immunol; 1996 Mar; 3(2):236-8. PubMed ID: 8991644
[TBL] [Abstract][Full Text] [Related]
16. Design and production of a target-specific monoclonal antibody to parvovirus B19 capsid proteins.
Kerr JR; O'Neill HJ; Deleys R; Wright C; Coyle PV
J Immunol Methods; 1995 Mar; 180(1):101-6. PubMed ID: 7534801
[TBL] [Abstract][Full Text] [Related]
17. IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay.
Manaresi E; Gallinella G; Zerbini M; Venturoli S; Gentilomi G; Musiani M
J Med Virol; 1999 Feb; 57(2):174-8. PubMed ID: 9892404
[TBL] [Abstract][Full Text] [Related]
18. Detection of human parvovirus B19-specific IgM and IgG antibodies using a recombinant viral VP1 antigen expressed in insect cells and estimation of time of infection by testing for antibody avidity.
Gray JJ; Cohen BJ; Desselberger U
J Virol Methods; 1993 Sep; 44(1):11-23. PubMed ID: 8227275
[TBL] [Abstract][Full Text] [Related]
19. Chronic human parvovirus B19 infection in rheumatic disease of childhood and adolescence.
Lehmann HW; Kühner L; Beckenlehner K; Müller-Godeffroy E; Heide KG; Küster RM; Modrow S
J Clin Virol; 2002 Aug; 25(2):135-43. PubMed ID: 12367647
[TBL] [Abstract][Full Text] [Related]
20. Follow-up study of clinical and immunological findings in patients presenting with acute parvovirus B19 infection.
Kerr JR; Coyle PV; DeLeys RJ; Patterson CC
J Med Virol; 1996 Jan; 48(1):68-75. PubMed ID: 8825713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
